Bartholomeus van Rhijn

About Bartholomeus van Rhijn

Bart Van Rhijn, also known as Bartholomeus van Rhijn, holds a senior leadership position at Nanobiotix as Chief Financial and Business Officer. He joined the French-listed biotechnology company in June 2021 and became part of its executive leadership structure, reflecting the importance of his role in guiding financial strategy, business development and international growth. At Nanobiotix, he supports the company’s expansion as it advances its clinical and commercial ambitions in the field of physics-based therapeutics. Before joining Nanobiotix, Van Rhijn spent nearly three years as Chief Financial Officer of Servier Pharmaceuticals in the United States. Earlier in his career, he held leadership roles at PricewaterhouseCoopers, Philips and Galderma, including Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance. This background gave him broad experience across corporate finance, tax strategy, M&A, operational restructuring and commercial scaling in both Europe and North America. Nanobiotix has described his track record as one focused on streamlining operations, driving growth and unlocking value. In practical terms, that profile is well suited to a biotech company navigating late-stage clinical development, global expansion and capital allocation discipline. His leadership is also associated with organizational health, team empowerment and a willingness to challenge the status quo while keeping patients and customers at the center of decision-making. Academically, he earned master’s degrees in Civil Law and Tax Law from Leiden University, an MBA with honors from Babson’s Olin School of Management, and a Certified Management Accountant designation. He also serves on the advisory board of a Boston-based healthcare start-up and is a venture partner at an emerging technology fund.